Therapeutic options for patients with clonal and idiopathic hypereosinophia

Expert Opinion on Investigational Drugs

Volumn 17, Issue 7, 2008, Pages 1039-1050

  Quintás Cardama, Alfonso ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alemtuzumab; FIP1L1 PDGFR ; HES; Imatinib; Mepolizumab

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CD52 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC AGENT; DASATINIB; ETOPOSIDE; EXEL 0862; FIP1 LIKE 1 PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA FUSION PROTEIN; FLUDARABINE; GLUCOCORTICOID; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MELPHALAN; MEPOLIZUMAB; MIDOSTAURIN; NILOTINIB; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RESLIZUMAB; SORAFENIB; STEROID; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ASTHMA; BONE MARROW BIOPSY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECG ABNORMALITY; ENDOCARDITIS; ENZYME INHIBITION; EOSINOPHIL COUNT; EOSINOPHILIA; GASTROINTESTINAL DISEASE; HEART ARREST; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HUMAN; HYPEREOSINOPHILIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENESIS; PROGNOSIS; REBOUND; REVIEW; SEPSIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ALGORITHMS; ANIMALS; EOSINOPHILIA; HUMANS; HYPEREOSINOPHILIC SYNDROME; IMMUNOTHERAPY; STEM CELL TRANSPLANTATION;

EID: 48249155731     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.7.1039     Document Type: Review

References (101)

1. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968;68:1220-9
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79
3. Cools J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14
4. Fauci AS, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97:78-92
5. Yoo TJ, et al. Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet Cytogenet 1984;11:389-94
6. Needleman SW, et al. Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol 1990;4:149-55
7. Chang HW, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999;93:1651-7
8. Higuchi W, et al. Hypercosinophilic syndrome terminating in acute myelogenous leukemia. Acta Haematol 1993;90:165-6
9. Luppi M, et al. Clonal nature of hypereosinophilic syndrome. Blood 1994;84:349-50
10. Cogan E, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-8
11. Brugnoni D, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 1996;87(4):1416-22
12. Simon HU, et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341(15):l112-20
13. Roufosse F, et al. Clonal The lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000;109(3):540-8
14. Cilloni D, et al. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia 2007;21(7):1442-50
15. Wilkins HJ, et al. Hypereosinophilic syndrome: an update. Am J Hematol 2005;80(2):148-57
16. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005;114(1):52-60
17. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22(1):14-22
18. Lefebvre C, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989;140(4):253-7
19. Spry CJ et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. QJ Med 1983;52(205):1-22
20. Dahabreh IJ, et al. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) 2007;86(6):344-54
21. Pitini V, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003;102(9):3456-7; author reply 3457
22. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978;89(2):167-72
23. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007;2:37
24. Butterfield JH, Gleich GJ. Interfiron-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994;121(9):648-53
25. Zielinski RM, Lawrence WD. Interferon-alpha for the hypereosinopbilic syndrome. Ann Intern Med 1990;113(9):716-8
26. Murphy PT, et al. Alfa-interferon in a case of hypereosinophilic syndrome. Br J Haematol 1990;75(4):619-20
27. Baratta L, et al. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy - case report and literature review. Angiology 2002;53(4):465-70
28. Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 1998;77(4):161-4
29. Luciano L, et al. AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 1999;84(7):651-3
30. Kioke T, Nakamura Y, Enokihara H. Interferon-alpha inhibits interleukin-5 and granulocyte-macrophage colony stimulating factor production by lymphocytes and suppresses eosinophil colony formation from bone marrow progenitor cells. Dokkyo J Med Sci 1998;25:45-52
31. Aldebert D, et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood 1996;87(6):2354-60
32. Schandene L, et al. Interferon-alpha upregulates both interleukin-10 and interferon-gamma production by human CD4+ T cells. Blood 1997;89(3):l110-1
33. Krishnaswamy G, et al. Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. J Interferon Cytokine Res 1996;16(10):819-27
34. Bletry O, Papo T. Interferons. Interferons alpha and gamma: indications in systemic diseases. Ann Med Interne (Paris) 1993;144(8):557-62
35. Coutant G, et al. Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases. Ann Med Interne (Paris) 1993;144(4):243-50
36. Demiroglu H, Dundar S. Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 1997;97(4):928-30
37. Cofrancesco E, et al. Response to vincristine treatment in a case of idiopathic hypereosinophilic syndrome with multiple clinical manifestations. Acta Haematol 1984;72(1):21-5
38. Marshall GM, White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1989;11(2):178-83
39. Sakamoto K, et al. Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1992;14(4):348-51
40. Ueno NT, et al. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia 1997;11(8):1386-90
41. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer 1991;67(11):2826-7
42. Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol 1991;62(6):230-1
43. Nadarajah S, et al. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics 1997;99(4):630-3
44. Archimbaud E, et al. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol 1988;27(4):302-3
45. Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15(4):647-8
46. Esteva-Lorenzo FJ, et al. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 1996;51(2):164-5
47. Fukushima T, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol 1995;90(1):213-5
48. Sadoun A, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant 1997;19(7):741-3
49. Vazquez L, et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant 2000;25(2):217-8
50. Juvonen E, et al. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 2002;29(5):457-8
51. Cooper MA, et al. Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant. Am J Hematol 2005;78(1):33-6
52. Ueno NT, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002;119(1):131-4
53. Halaburda K, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006;38(4):319-20
54. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypemosinophilia with imatinib mesylate. MedGenMed 2001;3(5):9
55. Pardanani A, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101(9):3391-7
56. Gleich GJ, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359(9317):1577-8
57. Ault P, et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002;26(9):881-4
58. Nolasco, I, Carvalho S, Parreira A, et al. Rapid and complete response to imatinib mesylate (STI-571) in a patient with idiopathic hypereosinophilia [abstract 346b]. Blood 2002; 100
59. Cortes J, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003;101(12):4714-6
60. Gorre ME, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-80
61. Khon AD, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004;103(2):473-8
62. Klion AD, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007;110(10):3552-6
63. Helbig G, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008;141(2):200-4
64. Gotlib J. Molecular classification and pathogenesis of easinophilic disorders: 2005 update. Acta Haematol 2005;114(1):7-25
65. Griffin JH, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl Acad Sci USA 2003;100(13):7830-5
66. Stover EH, et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006;103(21):8078-83
67. Score J, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006;20(5):827-32
68. Walz C, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006;45(10):950-6
69. Wilkinson K, et al. Cloning of the t(1;5) (q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003;102(12):4187-90
70. David M, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109(1):61-4
71. Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 2004;28(Suppl 1):S47-52
72. Metzgeroth G, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007;21(6):1183-8
73. Sato Y, et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive market of cardiac disorder. Intern Med 2000;39(4):350
74. Weisberg E, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7(2):129-41
75. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005;1754(1-2):3-13
76. O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65(11):4500-5
77. Verstovsek S, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 2006
78. Stover EH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005;106(9):3206-13
79. Cools J, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003;3(5):459-69
80. von Bubnoff N, et al. The FIP1L1-PDGFRA T6741 mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006;107(12):4970-1; author reply 4972
81. Kantarjian H, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354(24):2542-51
82. Le Coutre P, Hochhaus A, Heim D, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosinophilic syndrome (HES) [abstract 4912]. Blood 2006;108(11)
83. Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2- (6-(4-(2-hydroxyethyl)-piperazin-1-yl)- 2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47(27):6658-61
84. Schittenhelm MM, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66(1):473-81
85. Talpaz M, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531-41
86. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib (SPRYCEL) in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis [abstract 3551]. Blood 2007;110(11)
87. Strumberg D, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
88. Lierman E, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T6741 mutant. Blood 2006;108(4):1374-6
89. Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007;109(1):315-22
90. Pan J, et al. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 2007;21(7):1395-404
91. Fabbro D, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15(1):17-28
92. Chen J, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101(40):14479-84
93. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79(12):3101-9
94. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004;59(7):673-89
95. Klion AD, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004;103(8):2939-41
96. Hart TK, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108(2):250-7
97. Plotz SG, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349(24):2334-9
98. Rothenberg ME, et al. Treatment of patients with the hypereosinophic syndrome with mepolizumab. N Engl J Med 2008;358(12):1215-28
99. Sefcick A, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004;124(4):558-9
100. Pitini V, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004;127(5):477
101. Quintás-Cardama A, Tefferi A, Cortes J, et al. Alemtuzumab (CAMPATH-1H) is effective therapy for hypereosinophilic syndrome (HES) [abstract 4902]. Blood 2006;109(11)